CNS Pharmaceuticals, Inc. Amortization of Debt Discount (Premium)
CNS Pharmaceuticals, Inc. (CNSP) reported Amortization of Debt Discount (Premium) of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-12.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2021-02-12
- CNS Pharmaceuticals, Inc. amortization of debt discount (premium) for the quarter ending 2020-12-31 was $0.00.
- CNS Pharmaceuticals, Inc. amortization of debt discount (premium) for the quarter ending 2020-09-30 was $0.00.
- CNS Pharmaceuticals, Inc. amortization of debt discount (premium) for the quarter ending 2020-06-30 was $0.00, a 100.00% decline year-over-year.
- CNS Pharmaceuticals, Inc. amortization of debt discount (premium) for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- CNS Pharmaceuticals, Inc. amortization of debt discount (premium) for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- CNS Pharmaceuticals, Inc. amortization of debt discount (premium) for fiscal 2019 was $18.08K, a 0.00% change from fiscal 2018.
- CNS Pharmaceuticals, Inc. amortization of debt discount (premium) for fiscal 2018 was $18.08K.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $0.00 derived: sum of 2 quarters · filed 2021-02-12 | $0.00 derived: sum of 3 quarters · filed 2021-02-12 | $0.00 10-K · filed 2021-02-12 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-12 | $0.00 derived: sum of 2 quarters · filed 2020-11-12 | $0.00 10-Q · filed 2020-11-12 | $0.00 derived: sum of 4 quarters · filed 2021-02-12 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-10 | $0.00 10-Q · filed 2020-08-10 | $0.00 derived: sum of 3 quarters · filed 2021-02-12 | $0.00 derived: sum of 4 quarters · filed 2021-02-12 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-15 | $0.00 derived: sum of 2 quarters · filed 2021-02-12 | $0.00 derived: sum of 3 quarters · filed 2021-02-12 | $9.16K derived: sum of 4 quarters · filed 2021-02-12 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $0.00 derived: sum of 2 quarters · filed 2021-02-12 | $9.16K derived: sum of 3 quarters · filed 2021-02-12 | $18.08K 10-K · filed 2021-02-12 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-12 | $9.16K derived: sum of 2 quarters · filed 2020-11-12 | $18.08K 10-Q · filed 2020-11-12 | $21.42K derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $9.16K 10-Q · filed 2020-08-10 | $18.08K 10-Q · filed 2020-08-10 | $21.42K derived: sum of 3 quarters · filed 2020-08-10 | $34.09K derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $8.92K 10-Q · filed 2020-05-15 | $12.25K derived: sum of 2 quarters · filed 2020-05-15 | $24.92K derived: sum of 3 quarters · filed 2020-05-15 | |
| 2018-12-31 | $3.34K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $16.00K derived: sum of 2 quarters · filed 2020-03-12 | $18.08K 10-K · filed 2020-03-12 | |
| 2018-09-30 | $12.67K 10-Q · filed 2019-12-20 | $14.74K 10-Q · filed 2019-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |